Spire Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $66.8K | Buy |
205
+1
| +0.5% | +$326 | ﹤0.01% | 1110 |
|
|
2025
Q1 | $55.1K | Sell |
204
-1
| -0.5% | -$270 | ﹤0.01% | 1241 |
|
|
2024
Q4 | $48.3K | Sell |
205
-175
| -46% | -$41.3K | ﹤0.01% | 1298 |
|
|
2024
Q3 | $105K | Buy |
380
+3
| +0.8% | +$825 | ﹤0.01% | 903 |
|
|
2024
Q2 | $91.6K | Sell |
377
-206
| -35% | -$50.1K | ﹤0.01% | 917 |
|
|
2024
Q1 | $87.1K | Buy |
583
+3
| +0.5% | +$448 | ﹤0.01% | 1030 |
|
|
2023
Q4 | $107K | Hold |
580
| – | – | ﹤0.01% | 980 |
|
|
2023
Q3 | $103K | Sell |
580
-1
| -0.2% | -$177 | ﹤0.01% | 942 |
|
|
2023
Q2 | $110K | Sell |
581
-315
| -35% | -$59.8K | ﹤0.01% | 941 |
|
|
2023
Q1 | $179K | Buy |
896
+224
| +33% | +$44.9K | 0.01% | 765 |
|
|
2022
Q4 | $160K | Sell |
672
-13
| -2% | -$3.1K | 0.01% | 606 |
|
|
2022
Q3 | $137K | Sell |
685
-247
| -27% | -$49.4K | 0.01% | 616 |
|
|
2022
Q2 | $136K | Sell |
932
-418
| -31% | -$61K | 0.01% | 908 |
|
|
2022
Q1 | $221K | Buy |
1,350
+882
| +188% | +$144K | 0.01% | 847 |
|
|
2021
Q4 | $81K | Buy |
468
+9
| +2% | +$1.56K | ﹤0.01% | 1497 |
|
|
2021
Q3 | $87K | Hold |
459
| – | – | ﹤0.01% | 1243 |
|
|
2021
Q2 | $78K | Buy |
459
+22
| +5% | +$3.74K | ﹤0.01% | 1296 |
|
|
2021
Q1 | $62K | Buy |
+437
| New | +$62K | ﹤0.01% | 1616 |
|